Latest Intelligence on Oncology in Europe

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Leukemia: only 54% of Spaniards first present to PCP

Published By Datamonitor
31 May 2001
CommentWire
CommentWire

KS BioMedix: an alternative route to the marketplace

Published By Datamonitor
06 Nov 2000
Expert View
Expert View

Johnson & Johnson: Zytiga gains expanded prostate cancer indication in the US

Zytiga's indication expansion for the treatment of pre-chemotherapy castration-resistant metastatic prostate cancer significantly increases its commercial potential. However, potential competition from Xtandi may restrict sales.

Published By Datamonitor
13 Dec 2012
CommentWire
CommentWire

Janssen-Cilag: Velcade use extended in Europe

The EMEA has granted Velcade approval for use in the first-line treatment setting for multiple myeloma. With this line extension, Velcade will be available across all lines of multiple myeloma therapy, realizing its full commercial potential and offering a new treatment option to patients ineligible for bone marrow transplantation.

Published By Datamonitor
09 Sep 2008
Expert View
Expert View

J&J: physicians' familiarity with antihormonal agents will benefit new prostate cancer drug

Johnson & Johnson's abiraterone acetate in combination with prednisone has shown impressive improvement in overall survival in castrate-resistant metastatic prostate cancer patients who have progressed on treatment with chemotherapy. However, this is the third drug this year to have demonstrated a survival benefit in prostate cancer, and all three will vie for first-line use.

Published By Datamonitor
12 Oct 2010
Expert View
Expert View

Ironing out the Glivec-glitch

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, the National Institute of Clinical Excellence has decided to limit its use in chronic myeloid leukemia patients to the accelerated phase only, due to the lack of cost-effective data. Datamonitor's Oliver Luft investigates Glivec's costly delay and asks what can be done to prevent future hold-ups.

Published By Datamonitor
24 May 2002
CommentWire
CommentWire

Introgen: Advexin to face regulatory hurdles and increasing skepticism

Introgen Therapeutics has submitted marketing authorization applications for Advexin p53 therapy on both sides of the Atlantic. However, Introgen may struggle to convince the regulatory authorities that the gene therapy drug will offer an improvement in the treatment of head and neck cancer.

Published By Datamonitor
02 Jul 2008
CommentWire
CommentWire

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor
26 Nov 2001
CommentWire
CommentWire

Imclone/Merck KGaA: first approval for Erbitux

The Swiss agency for therapeutic products has approved Erbitux for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. This is likely to be followed by approval across Europe, where it should provide Merck KGaA [MRK.F] with annual sales of more than $260 million by 2008.

Published By Datamonitor
04 Dec 2003
CommentWire
CommentWire

ImClone Systems: Erbitux fortunes rally

The submission of Erbitux for marketing authorization in the European Union and Switzerland is the latest indication of a rally in ImClone Systems' [IMCL] fortunes following a rocky eighteen months. The European results also put ImClone's US licensing partner, Bristol Myers Squibb [BMY], a in a better position to try again for FDA approval.

Published By Datamonitor
16 Jul 2003

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.